Patent classifications
C07C237/10
Bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease
The invention relates to novel small molecule compounds having a basic structure as depicted by formula (A), where in particular exemplary embodiments R.sup.1 is —OH, R.sup.2 is —NO.sub.2 and R.sup.3 is H, R.sup.4 and R.sup.5 are H, one of R.sup.6 and R.sup.7 is selected from H, —CONH.sub.2, and —CONR.sup.9.sub.2, and the other one is selected from —CONR.sup.9.sub.2 and —CONR.sup.11R.sup.9, wherein R.sup.9 and R.sup.11 are (possibly multiply) substituted alkyl and H or alkyl, respectively. The compounds of the invention inhibit the enzyme Catechol-O-methyltransferase (COMT) and exhibit a low off-target profile. The compounds are provided for use as a medicament, in particular for use in prevention or treatment of Parkinson's disease.
Bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease
The invention relates to novel small molecule compounds having a basic structure as depicted by formula (A), where in particular exemplary embodiments R.sup.1 is —OH, R.sup.2 is —NO.sub.2 and R.sup.3 is H, R.sup.4 and R.sup.5 are H, one of R.sup.6 and R.sup.7 is selected from H, —CONH.sub.2, and —CONR.sup.9.sub.2, and the other one is selected from —CONR.sup.9.sub.2 and —CONR.sup.11R.sup.9, wherein R.sup.9 and R.sup.11 are (possibly multiply) substituted alkyl and H or alkyl, respectively. The compounds of the invention inhibit the enzyme Catechol-O-methyltransferase (COMT) and exhibit a low off-target profile. The compounds are provided for use as a medicament, in particular for use in prevention or treatment of Parkinson's disease.
ANTIMICROBIAL PHENOLIC FATTY ACID-BASED EPOXY CURING AGENTS FOR EPOXIES
Compositions containing at least one compound of formula I
##STR00001##
where R1 is a phenolic compound (e.g., simple phenol, creosote, thymol, or carvacrol), and where R2 is a polyamine (e.g., ethylenediamine (EDA), diethylenetriamine (DETA), triethylenetetramine (TETA), tetraethylenepentamine (TEPA), hexamethylenediamine (HDA)); and optionally a carrier; the compositions may additionally contain at least one epoxy resin. Methods for killing microorganisms involving contacting the microorganisms with an effective microorganism killing amount of the above composition. Compositions containing at least one compound produced by a method involving reacting phenolic-branched chain fatty acid methyl ester with at least one polyamine.
COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES
The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.
##STR00001##
COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES
The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.
##STR00001##
AMIDODIAMINE CORROSION INHIBITORS
Methods for providing corrosion inhibition in conduits, containers, and wellbores penetrating subterranean formations are provided. In some embodiments, the methods comprise contacting a metal surface with a fluid comprising a corrosion inhibitor additive. In certain embodiments, the corrosion inhibitor additive comprises a compound comprising a hydrophobic cation moiety, one or more lipophilic tails, and a linking moiety.
AMIDODIAMINE CORROSION INHIBITORS
Methods for providing corrosion inhibition in conduits, containers, and wellbores penetrating subterranean formations are provided. In some embodiments, the methods comprise contacting a metal surface with a fluid comprising a corrosion inhibitor additive. In certain embodiments, the corrosion inhibitor additive comprises a compound comprising a hydrophobic cation moiety, one or more lipophilic tails, and a linking moiety.
Agents for improved delivery of nucleic acids to eukaryotic cells
New cationic lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes.
Agents for improved delivery of nucleic acids to eukaryotic cells
New cationic lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes.
Organ preservation composition
An aqueous organ preservation solution includes taurine and L-alanine-L-glutamine and glutamic acid. The organ preservation composition can be stored in a solid state, for example in the form of small particles (e.g. a powder or micronized powder), and be dissolved in water, thereby instantly providing a ready-to-use organ preservation solution.